Ertugliflozin L-pyroglutamic acid
Ertugliflozin L-pyroglutamic acid is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatment of type 2 diabetes mellitus. (In Vitro) :Ertugliflozin L-pyroglutamic acid demonstrated >2000-fold selectivity for SGLT2 over SGLT. (In Vivo) :The oral administration of Ertugliflozin L-pyroglutamic to rats acid showed concentration-dependent glucosuria.
Product Specifications
CAS Number
1210344-83-4
Product Name Alternative
PF-04971729 L-pyroglutamic acid
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : ≥ 125 mg/mL (220.85 mM)
Smiles
OC (=O) [C@@H]1CCC (=O) N1.CCOc1ccc (Cc2cc (ccc2Cl) [C@]23OC[C@] (CO) (O2) [C@@H] (O) [C@H] (O) [C@H]3O) cc1
Molecular Formula
C27H32ClNO10
Molecular Weight
566
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CLIA kit for Human FABP8 (Fatty Acid Binding Protein 8, Myelin)